Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

被引：0
|
作者：
Hideyasu Matsuyama
Nobuaki Matsubara
Hirotaka Kazama
Takeshi Seto
Shoko Tsukube
Kazuhiro Suzuki
机构：
[1] Yamaguchi University,Department of Urology, Graduate School of Medicine
[2] Department of Breast and Medical Oncology,Department of Urology
[3] National Cancer Center Hospital East,undefined
[4] Sanofi Genzyme Oncology Medical,undefined
[5] Sanofi K.K.,undefined
[6] Medical Affairs,undefined
[7] Sanofi K.K.,undefined
[8] Gunma University Graduate School of Medicine,undefined
来源：
BMC Cancer | / 20卷
关键词：
Cabazitaxel; Castration-resistant prostate cancer; Post-marketing surveillance; Japan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study
    Matsuyama, Hideyasu
    Matsubara, Nobuaki
    Kazama, Hirotaka
    Seto, Takeshi
    Tsukube, Shoko
    Suzuki, Kazuhiro
    BMC CANCER, 2020, 20 (01)
  • [2] Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study
    Suzuki, Kazuhiro
    Matsubara, Nobuaki
    Kazama, Hirotaka
    Seto, Takeshi
    Tsukube, Shoko
    Matsuyama, Hideyasu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (12) : 1157 - 1163
  • [3] Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan
    Matsubara, Nobuaki
    Suzuki, Kazuhiro
    Kazama, Hirotaka
    Tsukube, Shoko
    Seto, Takeshi
    Matsuyama, Hideyasu
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (07) : 1067 - 1073
  • [4] Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
    Yamamoto, Teppei
    Ishizuka, Osamu
    Oike, Hiroshi
    Shiozaki, Masashi
    Haba, Tomomi
    Oguchi, Tomohiko
    Iijima, Kazuyoshi
    Kato, Haruaki
    PROSTATE INTERNATIONAL, 2020, 8 (01) : 27 - 33
  • [5] Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer
    Hori, Akiyo
    Sahashi, Haruka
    Sano, Sora
    Matsumiya, Emiri
    Ariga, Maho
    Asano, Akari
    Soda, Midori
    Goto, Chitoshi
    Mizui, Takashi
    Komeda, Hisao
    Kitaichi, Kiyoyuki
    ANTICANCER RESEARCH, 2020, 40 (12) : 7101 - 7108
  • [6] Post marketing surveillance study of cabazitaxel (CBZ) in Japanese patients with castration resistant prostate cancer (CRPC) in real world settings.
    Matsuyama, Hideyasu
    Matsubara, Nobuaki
    Taguchi, Tomoyuki
    Seto, Takeshi
    Suzuki, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [7] Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study
    Koroki, Yosuke
    Imanaka, Keiichiro
    Yasuda, Yukiko
    Harada, Sayuri
    Fujino, Akiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (09) : 1452 - 1461
  • [8] Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan
    Matsuyama, Hideyasu
    Matsubara, Nobuaki
    Kazama, Hirotaka
    Seto, Takeshi
    Sunaga, Yoshinori
    Suzuki, Kazuhiro
    BMC CANCER, 2023, 23 (01)
  • [9] Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan
    Hideyasu Matsuyama
    Nobuaki Matsubara
    Hirotaka Kazama
    Takeshi Seto
    Yoshinori Sunaga
    Kazuhiro Suzuki
    BMC Cancer, 23
  • [10] Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA
    Eisenberger, Mario
    Hardy-Bessard, Anne-Claire
    Kim, Choung Soo
    Geczi, Lajos
    Ford, Daniel
    Mourey, Loic
    Carles, Joan
    Parente, Phillip
    Font, Albert
    Kacso, Gabriel
    Chadjaa, Mustapha
    Zhang, Wenping
    Bernard, John
    de Bono, Johann
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3198 - +
12345